Switching to Tenecteplase for Stroke Thrombolysis

医学 特奈特普酶 溶栓 冲程(发动机) 内科学 心脏病学 组织纤溶酶原激活剂 急性中风 纤溶剂 机械工程 工程类 心肌梗塞
作者
Karim Mahawish,John Gommans,Timothy Kleinig,Bhavesh Lallu,Alicia Tyson,Annemarei Ranta
出处
期刊:Stroke [Ovid Technologies (Wolters Kluwer)]
卷期号:52 (10) 被引量:56
标识
DOI:10.1161/strokeaha.121.035931
摘要

Background and Purpose: Due to practical advantages, increasing trial safety data, recent Australian Guideline endorsement and local population needs we switched to tenecteplase for stroke thrombolysis from alteplase. We describe our change process and real-world outcome data. Methods: Mixed-methods including stakeholder engagement, preimplementation and postimplementation surveys, and assessment of patient treatment rates, metrics, and clinical outcomes preimplementation and postimplementation adjusting regression analyses for age, sex, National Institutes of Health Stroke Scale, premorbid modified Rankin Scale score, and thrombectomy using New Zealand National Stroke Registry data. Results: Preswitch consultation involved stroke and emergency clinicians, pharmacists, national regulatory bodies, and hospital legal teams. All survey responders (90% response rate) supported the proposed change and remained satisfied 12 months postimplementation. Between January 2018 and February 2021, we treated 555 patients with alteplase and 283 with tenecteplase. Patients treated with tenecteplase had greater odds of a favorable modified Rankin Scale using both shift (adjusted odds ratio, 1.60 [95% CI, 1.15–2.22]) and dichotomous analyses (modified Rankin Scale score, 0–2; adjusted odds ratio, 2.17 [95% CI, 1.31–3.59]) and shorter median (interquartile range) door-to-needle time (median, 53 [38–73.5] versus 61 minutes [45–85], P =0.0002). Symptomatic intracranial hemorrhage rates (tenecteplase 1.8% versus 3.4%; adjusted odds ratio, 0.46 [95% CI, 0.13–1.64]), death by day 7 (tenecteplase 7.5% versus 11.8%; adjusted odds ratio, 0.46 [95% CI, 0.21–0.99]), and median (interquartile range) needle to groin time for the 42 transferred regional patients (tenecteplase 155 [113–248] versus 200 [158–266]; P =0.27) did not significantly differ. Conclusions: Following stakeholder endorsement, a region-wide switch from alteplase to tenecteplase was successfully implemented. We found evidence of benefit and no evidence of harm.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
4秒前
么么鸭宝宝给么么鸭宝宝的求助进行了留言
4秒前
xixi发布了新的文献求助10
5秒前
苻醉山发布了新的文献求助10
5秒前
完美世界应助孔秋词采纳,获得10
5秒前
6秒前
JETSTREAM完成签到,获得积分10
9秒前
10秒前
鱼儿会飞完成签到,获得积分10
11秒前
11秒前
13秒前
萧水白应助新星采纳,获得10
13秒前
乐萱完成签到,获得积分10
13秒前
森sen发布了新的文献求助30
13秒前
JamesPei应助sys采纳,获得30
14秒前
paltahun完成签到,获得积分10
15秒前
Lilyzi应助科研通管家采纳,获得10
15秒前
orixero应助科研通管家采纳,获得10
15秒前
Owen应助科研通管家采纳,获得10
15秒前
ding应助科研通管家采纳,获得10
15秒前
充电宝应助科研通管家采纳,获得10
15秒前
Billy应助科研通管家采纳,获得30
15秒前
Billy应助科研通管家采纳,获得30
15秒前
15秒前
热情依白完成签到 ,获得积分10
17秒前
飘逸的巧凡完成签到,获得积分20
17秒前
细腻的海露完成签到,获得积分20
18秒前
我想毕业完成签到,获得积分10
19秒前
19秒前
领导范儿应助跳跃仙人掌采纳,获得20
20秒前
Aurora发布了新的文献求助10
20秒前
周老八发布了新的文献求助10
20秒前
20秒前
万能图书馆应助拓跋傲薇采纳,获得10
21秒前
我想毕业发布了新的文献求助10
21秒前
paltahun发布了新的文献求助10
22秒前
Dr.Li完成签到,获得积分20
22秒前
Cuisine完成签到,获得积分10
23秒前
自觉从筠完成签到 ,获得积分10
26秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Very-high-order BVD Schemes Using β-variable THINC Method 870
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
Fundamentals of Dispersed Multiphase Flows 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3254315
求助须知:如何正确求助?哪些是违规求助? 2896538
关于积分的说明 8293128
捐赠科研通 2565468
什么是DOI,文献DOI怎么找? 1393064
科研通“疑难数据库(出版商)”最低求助积分说明 652418
邀请新用户注册赠送积分活动 629894